Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B21 adjuvant pembrolizumab in high-risk endometrial cancer
jRCT2031200399Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoints: Disease-free survival by investigator assessment or histopathologic confirmation and Overall survival. Started Mar 2021; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on jRCT2031200399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200399.